Daily treatment with IPL344 for up to three years was safe and appeared to slow amyotrophic lateral sclerosis (ALS) progression, according to recently published data from a small Phase 2a clinical trial. Patients undergoing treatment gained weight and experienced slower declines in functional abilities and lung function. The…
The ALS Association is teaming with the workplace learning company Schoox to provide education resources for patients, caregivers, healthcare providers, and others affected by amyotrophic lateral sclerosis (ALS). With this partnership, Schoox will provide fast and easy access to a range of resources, including educational materials and…
Taking statins to lower cholesterol does not affect survival outcomes for people with amyotrophic lateral sclerosis (ALS), researchers in Norway have found. In a study of ALS patients using national health registry data, the scientists compared the life expectancy of statin users and nonusers. According to the team, “statin use…
Get regular updates to your inbox.
